1FDA. FDA approves new antiplatelet drug used during heart procedure[ EB/OL ]. [ 2015 - 06 - 22]. http ://www. fda. gov/newsevents/newsroom/pressannouncements/ ucm 4521 72. htm.
2INGALL A H, CAGE P A, KINDON N D, et al. N-Alkyl-2- substituted ATP analogues: WO, 1994018216 [ P ]. 1994 - 02 - 08.
3INGALL A H,DIXON J,BAILEY A. Antagonists of the plate- let P2T receptor: a novel approach to antithrombotic thera- py[ J], J Meal Chem, 1999,42:213 - 220.
4FDA. FDA briefing document for the cardiovascular and renal drugs advisory committee [ EB/OL ]. [ 2015 - 04 - 15 ]. ht- tp://www, fda. gov/downloads/advisorycommittees/com- drugs/cardiovascularandrenaldrug- sadvisorycommittee/ucm442199, pdf.
5FDA. KENGREALTM (cangrelor) for injection, for intrave- nous use. [ EB/OL]. [ 2015 - 06 - 22 ]. http ://www. access- data. fda. gov/drugsatfda docs/label/2015/2049581bl, pdf.
